| 前收市價 | 167.89 |
| 開市 | 168.59 |
| 買盤 | 170.22 x 800 |
| 賣出價 | 170.28 x 800 |
| 今日波幅 | 168.29 - 170.32 |
| 52 週波幅 | 130.96 - 182.89 |
| 成交量 | |
| 平均成交量 | 5,645,112 |
| 市值 | 301.152B |
| Beta 值 (5 年，每月) | 0.56 |
| 市盈率 (最近 12 個月) | 62.53 |
| 每股盈利 (最近 12 個月) | 2.72 |
| 業績公佈日 | 2024年4月26日 |
| 遠期股息及收益率 | 6.20 (3.69%) |
| 除息日 | 2024年4月12日 |
| 1 年預測目標價 | 184.70 |
ZacksEli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksGear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
ZacksAbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
